156 related articles for article (PubMed ID: 9157072)
1. Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients.
Schilling T; Fiebig HH; Kerpel-Fronius S; Winterhalter B; Variol P; Tresca P; Heinrich B; Hanauske AR
Invest New Drugs; 1996; 14(4):371-8. PubMed ID: 9157072
[TBL] [Abstract][Full Text] [Related]
2. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT
Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma.
Hutson TE; Ganapathi R; Elson P; Mekhail T; Olencki T; Budd GT; Bukowski RM
Invest New Drugs; 2004 Aug; 22(3):277-84. PubMed ID: 15122074
[TBL] [Abstract][Full Text] [Related]
5. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation.
Ibrahim NK; Valero V; Rahman Z; Theriault RL; Walters RS; Buzdar AU; Booser DJ; Holmes FA; Murray JL; Willey J; Bast R; Hortobagyi GN
Cancer Invest; 2001; 19(5):459-66. PubMed ID: 11458813
[TBL] [Abstract][Full Text] [Related]
8. Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study.
Gridelli C; Guida C; Barletta E; Gatani T; Fiore F; Barzelloni ML; Rossi A; de Bellis M; D'Aniello R; Scognamiglio F
Lung Cancer; 2000 Aug; 29(2):131-7. PubMed ID: 10963843
[TBL] [Abstract][Full Text] [Related]
9. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.
Toussaint C; Izzo J; Spielmann M; Merle S; May-Levin F; Armand JP; Lacombe D; Tursz T; Sunderland M; Chabot GG
J Clin Oncol; 1994 Oct; 12(10):2102-12. PubMed ID: 7931480
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC).
Bonneterre J; Chevalier B; Focan C; Mauriac L; Piccart M
Ann Oncol; 2001 Dec; 12(12):1683-91. PubMed ID: 11843245
[TBL] [Abstract][Full Text] [Related]
12. A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies.
Delord JP; Raymond E; Chaouche M; Ruffie P; Ducreux M; Faivre S; Boige V; Le Chevalier T; Rixe O; Baudin E; Pautier P; Rodier JM; Chouaki N; Escudier B; Kayitalire L; Armand JP
Ann Oncol; 2000 Jan; 11(1):73-9. PubMed ID: 10690391
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor.
Yang SH; Lin CC; Lin ZZ; Tseng YL; Hong RL
Invest New Drugs; 2012 Feb; 30(1):282-9. PubMed ID: 20809205
[TBL] [Abstract][Full Text] [Related]
14. Continuous-infusion vinorelbine for the treatment of advanced non-small-cell lung cancer: a phase I/II study.
Carabante-Ocón F; Cobo-Dols M; Benavides-Orgaz M; Gil-Calle S; Alés-Díaz I; Bretón-García JJ; Villar-Chamorro E; Montesa-Pino A; Alcalde-García J; Gutiérrez-Calderón V
Clin Lung Cancer; 2005 Sep; 7(2):121-6. PubMed ID: 16179099
[TBL] [Abstract][Full Text] [Related]
15. The effects of food and divided dosing on the bioavailability of oral vinorelbine.
Rowinsky EK; Lucas VS; Hsieh AL; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Donehower RC
Cancer Chemother Pharmacol; 1996; 39(1-2):9-16. PubMed ID: 8995494
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of a daily x4 schedule of vinorelbine plus cisplatin for advanced non-small cell lung cancer.
Han JY; Kim KW; Kim JA; Kang JH; Jin JY; Hong YS; Park SY; Song JS; Park JW; Kim HK; Lee KS; Choi BG
Jpn J Clin Oncol; 2000 Oct; 30(10):435-9. PubMed ID: 11185889
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer.
Crawford J; O'Rourke M; Schiller JH; Spiridonidis CH; Yanovich S; Ozer H; Langleben A; Hutchins L; Koletsky A; Clamon G; Burman S; White R; Hohneker J
J Clin Oncol; 1996 Oct; 14(10):2774-84. PubMed ID: 8874339
[TBL] [Abstract][Full Text] [Related]
20. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel--a phase II study.
Fazeny B; Zifko U; Meryn S; Huber H; Grisold W; Dittrich C
Cancer Chemother Pharmacol; 1996; 39(1-2):150-6. PubMed ID: 8995513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
